<DOC>
	<DOCNO>NCT01897207</DOCNO>
	<brief_summary>The main aim trial assess response rate , feasibility toxicity treatment antigen load Dendritic Cell Vaccination Prostate Cancer patient . Furthermore want investigate biological response measure marker in-vivo ex-vivo immunomodulation .</brief_summary>
	<brief_title>Phase I/II Study Vaccination With Antigen Loaded Dendritic Cells ( DCs ) Hormone-Refractory Prostate Cancer</brief_title>
	<detailed_description>Dendritic cell ( DC ) -based immunotherapy promise approach augment tumor antigen-specific T cell response cancer patient . However , tumor escape down-regulation complete loss target antigen may limit susceptibility tumor cell immune attack . Concomitant generation T cell responses several immunodominant antigen may circumvent potential drawback . In phase I/II clinical trial , investigator determine immunostimulatory capacity autologous DC pulse multiple T cell epitopes derive four different prostate-specific antigen patient advance hormone-refractory prostate cancer . Autologous DC HLA-A*0201-positive patient load antigenic peptide derive prostate stem cell antigen , prostatic acid phosphatase , prostate-specific membrane antigen , prostate-specific antigen . A strict quality control concern expression surface marker migratory capacity DC secure optimal stimulatory capacity . DC apply intradermally six time biweekly interval follow monthly booster injection . Tolerability PSA response investigate . Antigen-specific immune response quantify .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>histologically cytologically proven prostatic carcinoma proven hormonal resistance : tumor progression orchiectomy treatment hormonal agent . Patients treat antiandrogens , flutamide ( Flucinom ) bicalutamide ( Casodex ) , discontinue drug 6 week prior trial entry follow tumor response within 6 week amenable curative therapy patient measurable nonmeasurable disease may include . Bone lesion consider nonmeasurable two consecutive increase prostatespecific antigen ( PSA ) document previous reference value ( N째1 ) . The first increase PSA ( N째2 ) occur minimum one week reference value confirm ( N째3 ) . If value le previous value , patient still eligible next PSA ( N째4 ) find high second PSA . Serum level prostatespecific antigen must least 10 microg/l Previous radiotherapy allow stop 4 week trial treatment involve lesion use evaluate activity trial drug one previous chemotherapy ( include Estracyt ) allow , chemotherapy stop least 6 week study entry age &gt; 18 year performance status 0,1,2 ( ECOG , Appendix I ) concurrent therapy steroid uncontrolled infection live expectancy 3 month Human leukocyte antigen ( HLA ) Type HLA*A201 neutrophile count &gt; 1500/microl thrombocyte &gt; 100 000/microl creatinine &lt; 1.5 upper normal level adequate liver function bilirubin &lt; 2 upper normal level , alanine aminotransferase ( ALAT ) aspartate transamionase ( ASAT ) &lt; 3 x upper normal level absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial patient registration/randomization , informed consent must give accord good clinical practice ( GCP ) , national/local regulation serious concomitant disease ( cardiac , pulmonary others ) brain metastasis previous splenectomy radiotherapy spleen concurrent therapy immunosuppressive drug chronic immunosuppression ( include transplantation HIVinfection ) HIV , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) ( test require ) severe uncontrolled infection neoplastic disease except : curatively treat basal cell squamous cell carcinoma skin relapse free 5 year curative treatment neoplasm treatment investigational drug last month severe autoimmune disease chemotherapy , radiotherapy immunotherapy le 6 week study entry Ejection fraction ( measure echocardiography ) &lt; 40 %</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>dendritic cell</keyword>
	<keyword>vaccination</keyword>
</DOC>